Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, Hultcrantz M, Hassoun H, Lu SX, Tan C, Rustad EH, Maura F, Maclachlan K, Peterson T, Derkach A, Devlin S, Landau HJ, Scordo M, Chung DJ, Shah GL, Lahoud O, Thoren K, Murata K, Ramanathan L, Arcila ME, Ho C, Roshal M, Dogan A, Giralt SA, Landgren O.
Diamond B, et al. Among authors: hultcrantz m.
Lancet Haematol. 2021 Jun;8(6):e422-e432. doi: 10.1016/S2352-3026(21)00130-7.
Lancet Haematol. 2021.
PMID: 34048681
Clinical Trial.